DexCom (DXCM) Q2 2026 Earnings Call Transcript
DexCom (DXCM) reported Q2 2026 revenue of $1.31B, up 13% reported and 12% organic year over year. Non-GAAP gross margin was 64.1%, non-GAAP operating income $328.3M, and non-GAAP EPS $0.70. Free cash flow was $600M in H1. FY2026 revenue guidance raised to $5.18B-$5.25B. The company completed the Nutrisense acquisition and discussed CONNECT trial and G7 15-day progress.
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised FY2026 guidance (revenue and margins), the large buyback authorization execution, and specific milestones tied to coverage and product platform timelines.
Market read
DexCom’s raised guidance and margin improvement, alongside reimbursement and product milestones, provide fresh inputs for CGM sector positioning and near-term valuation.
What to watch
CMS coverage decision is a key catalyst with an estimated effective date mid-2027, so near-term valuation may hinge more on reimbursement narrative than on current quarter fundamentals.
Background
The text is a DexCom Q2 2026 earnings call transcript covering financial results, guidance, clinical and regulatory updates, and capital allocation.
Ticker impact
DexCom reported Q2 results and raised FY2026 revenue guidance to $5.18B-$5.25B, plus lifted gross and operating margin guidance.
Near-term bias higher as traders reprice FY margin and growth expectations; follow-through depends on CMS coverage decision timing and FX headwinds.
The article discloses multiple concrete, decision-relevant datapoints: Q2 revenue/EPS, raised FY guidance (revenue, gross margin, operating margin), $600M buyback, and specific regulatory/clinical milestones (Health Canada clearance, CONNECT trial results, FDA Tempo pilot).
Market effects
CGM peers may see read-across on type 2 non-insulin coverage momentum and extended-wear adoption economics.
International growth strength (France, Canada) offsets FX headwinds, which may influence how traders model ex-US demand for medtech/diabetes tech.
Health Canada clearance for the G7 15-day configuration supports broader international commercialization expectations for CGM hardware.
Counterpoint
Raised guidance could still be vulnerable to execution risk from Ireland factory ramp costs and FX-driven international revenue pressure in 2H26.
Key entities
- companyDexCom
CGM provider reporting Q2 2026 results, raised FY2026 guidance, and sharing clinical, regulatory, and product roadmap updates.
- regulatorCMS
U.S. Centers for Medicare & Medicaid Services, referenced for a coverage decision for non-insulin type 2 population by end of 2026.
- regulatorFDA
Referenced for the Tempo digital device pilot and metabolic health screening pathway using DexCom CGM.
- acquisitionNutrisense
Nutrition insights acquisition completed in Q2 2026, described as immaterial to non-CGM revenue currently.
